FDA grants Breakthrough Therapy designation to Duchenne muscular dystrophy therapeutic This recognition signals momentum for next-gen RNA therapeutics designed to enhance delivery and efficacy in treating rare genetic diseases.

https://www.drugdiscoverynews.com/fda-grants-breakthrough-therapy-designation-to-first-in-class-aoc-therapeutic-for-duchenne-muscular-dystrophy-16530